Manos Perros | President & CEO
Entasis Therapeutics

Manos Perros, President & CEO, Entasis Therapeutics

Dr. Manos Perros is President and Chief Executive Officer of Entasis Therapeutics.  Manos was central to the establishment of Entasis Therapeutics, and led talks with AstraZeneca that resulted in the creation of the new company in 2015.  Manos was Vice President of the Innovative medicines and Early Development unit of and Head of AstraZeneca’s Infection Innovative Medicines organization for more than four years, and also served as Site Head, for AstraZeneca’s Boston R&D research centre and Gatehouse Park BioHub in Waltham, MA. In his role as the Infection Head, Manos was accountable for the Infection delivery from idea to clinical proof-of-concept of a portfolio of programs against serious bacterial infections, respiratory viruses, and neglected infectious diseases (tuberculosis and malaria in particular). Manos was also the executive sponsor for the Global Chemistry Leadership team at AstraZeneca, and led the evolution of the organizational and sourcing model, including the establishment of a strategic partnership with Pharmaron (China). A chemist by training, Manos conducted his PhD work in Belgium, France and Germany, and was Associate in the Biophysics department at Yale from 1993-1995. Prior to joining AstraZeneca, Manos served as Director of the Novartis Institute for Tropical Diseases in Singapore, and prior to that, as Vice-President and Chief Scientific Officer, Antivirals, at Pfizer. Manos has overseen a wide range of therapeutic areas, but his greatest contributions have been in the field of anti-infectives, where he is a distinguished and widely published scientist, having led research projects against HIV, Hepatitis C, influenza and fungal pathogens. Amongst a number of molecules still in development, Manos is a co-inventor of the first-in-class HIV treatment maraviroc (Celsentri/Selzentry) on which he worked from inception to launch. The medicine earned numerous accolades, including the 2008 Prix Galien USA. For his contributions to the discovery and development of maraviroc, Manos received the PhRMA Discoverer’s Award in 2010.

Appearances:



World Anti-Microbial Resistance Congress USA 2018 - Day 1 @ 17:30

Keynote CEO Panel: How to do business in a challenging environment - Current landscape for biotechs looking to commercialize or commercializing antimicrobials

  • How do you turn the current antibiotic development and commercialization model into one that is attractive to big pharma
  • Partnering and business development opportunities for smaller antibiotic biotechs – overcoming low stock prices
  • How can developing companies survive in this space and get continuous investments? Is the emergence of smaller companies the way to commercial viability and efficient distribution of resources
  • What is the investment landscape going to look like for up and coming companies
  • How to launch a product and demonstrate commercial success
last published: 12/Oct/18 20:55 GMT

back to speakers